News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
TransOral Pharmaceuticals, Inc. Swallows $23M Series C
October 31, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Life science investors looking to mitigate their risk profile have shown confidence in TransOral Pharmaceuticals Inc. by investing $23 million in Series C financing as it teeters on the brink of late-stage clinical development.
Twitter
LinkedIn
Facebook
Email
Print
Startups
MORE ON THIS TOPIC
Layoff Tracker
Ultragenyx Downsizes By 10% After Bone Drug’s Phase 3 Fail
February 13, 2026
·
54 min read
·
BioSpace Editorial Staff
Vaccines
Flu Vaccine Rejection Imperils Moderna’s Breakeven Plans
February 12, 2026
·
4 min read
·
Dan Samorodnitsky
People
Sanofi Shares Decline as Paul Hudson Removed as CEO, Making Way For Merck KGaA’s Belén Garijo
February 12, 2026
·
2 min read
·
Annalee Armstrong
Insights
Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment
February 12, 2026
·
1 min read
·
Jennifer Smith-Parker
